Skip to Main Content

Paper Details

The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.
Mult Scler Relat Disord
6
2022
B, B-, B-cell, CD20 B, CD20 B-cells, CELLO, CNS lesions, MS, Ocrelizumab, Participants, Patients, RIS, blood and CSF immune cells, brain atrophy, brain lesions, cognitive impairment, humanized, intrathecal inflammation, multiple sclerosis, ocrelizumab, participants, patient, patients, radiologically isolated syndrome, relapsing and primary progressive MS, single
Author NameAffiliation
Erin E LongbrakeYale School of Medicine
Anne H CrossWashington University School of Medicine
David A HaflerYale School of Medicine
David A HaflerYale School of Medicine
  • 1 - 4

Datasets

Release 1.2